Contact, publication, and social network information about Harvard faculty and fellows. Harvard Catalyst Profiles
Keywords
Last Name
Institution

Aldo M. Roccaro, M.D.

TitleResearch Associate in Medicine
InstitutionDana-Farber Cancer Institute
DepartmentMedicine
AddressDana Farber Cancer Institute
Medical Oncology - Mayer/M549
44 Binney St
Boston MA 02115
Phone617/582-8535
Fax617/632-8608

 Bibliographic 
 selected publications
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
List All   |   Timeline
  1. Bianchi G, Sacco A, Kumar S, Rossi G, Ghobrial I, Roccaro A. Candidate genes of Waldenström's macroglobulinemia: current evidence and research. Appl Clin Genet. 2013; 6:33-42.
    View in: PubMed
  2. Moschetta M, Basile A, Ferrucci A, Frassanito MA, Rao L, Ria R, Solimando AG, Giuliani N, Boccarelli A, Fumarola F, Coluccia M, Rossini B, Ruggieri S, Nico B, Maiorano E, Ribatti D, Roccaro AM, Vacca A. Novel targeting of phospho-cMET overcomes drug resistance and induces antitumor activity in multiple myeloma. Clin Cancer Res. 2013 Aug 15; 19(16):4371-82.
    View in: PubMed
  3. Liu Y, Quang P, Braggio E, Ngo H, Badalian-Very G, Flores L, Zhang Y, Sacco A, Maiso P, Azab AK, Azab F, Carrasco R, Rollins BJ, Roccaro AM, Ghobrial IM. Novel Tumor Suppressor Function of Glucocorticoid-Induced TNF Receptor GITR in Multiple Myeloma. PLoS One. 2013; 8(6):e66982.
    View in: PubMed
  4. Roccaro AM, Sacco A, Maiso P, Azab AK, Tai YT, Reagan M, Azab F, Flores LM, Campigotto F, Weller E, Anderson KC, Scadden DT, Ghobrial IM. BM mesenchymal stromal cell-derived exosomes facilitate multiple myeloma progression. J Clin Invest. 2013 Apr 1; 123(4):1542-55.
    View in: PubMed
  5. Sacco A, Zhang Y, Maiso P, Manier S, Rossi G, Treon SP, Ghobrial IM, Roccaro AM. microRNA Aberrations in Waldenström Macroglobulinemia. Clin Lymphoma Myeloma Leuk. 2013 Apr; 13(2):205-7.
    View in: PubMed
  6. Roccaro AM, Sacco A, Jia X, Banwait R, Maiso P, Azab F, Flores L, Manier S, Azab AK, Ghobrial IM. Mechanisms of Activity of the TORC1 Inhibitor Everolimus in Waldenstrom Macroglobulinemia. Clin Cancer Res. 2012 Dec 15; 18(24):6609-22.
    View in: PubMed
  7. Manier S, Sacco A, Leleu X, Ghobrial IM, Roccaro AM. Bone marrow microenvironment in multiple myeloma progression. J Biomed Biotechnol. 2012; 2012:157496.
    View in: PubMed
  8. Cea M, Cagnetta A, Fulciniti M, Tai YT, Hideshima T, Chauhan D, Roccaro A, Sacco A, Calimeri T, Cottini F, Jakubikova J, Kong SY, Patrone F, Nencioni A, Gobbi M, Richardson P, Munshi N, Anderson KC. Targeting NAD+ salvage pathway induces autophagy in multiple myeloma cells via mTORC1 and extracellular signal-regulated kinase (ERK1/2) inhibition. Blood. 2012 Oct 25; 120(17):3519-29.
    View in: PubMed
  9. Blotta S, Jakubikova J, Calimeri T, Roccaro AM, Amodio N, Azab AK, Foresta U, Mitsiades CS, Rossi M, Todoerti K, Molica S, Morabito F, Neri A, Tagliaferri P, Tassone P, Anderson KC, Munshi NC. Canonical and noncanonical Hedgehog pathway in the pathogenesis of multiple myeloma. Blood. 2012 Dec 13; 120(25):5002-13.
    View in: PubMed
  10. Zhang Y, Roccaro AM, Rombaoa C, Flores L, Obad S, Fernandes SM, Sacco A, Liu Y, Ngo H, Quang P, Azab AK, Azab F, Maiso P, Reagan M, Brown JR, Thai TH, Kauppinen S, Ghobrial IM. LNA-mediated anti-miR-155 silencing in low-grade B-cell lymphomas. Blood. 2012 Aug 23; 120(8):1678-86.
    View in: PubMed
  11. Azab AK, Hu J, Quang P, Azab F, Pitsillides C, Awwad R, Thompson B, Maiso P, Sun JD, Hart CP, Roccaro AM, Sacco A, Ngo HT, Lin CP, Kung AL, Carrasco RD, Vanderkerken K, Ghobrial IM. Hypoxia promotes dissemination of multiple myeloma through acquisition of epithelial to mesenchymal transition-like features. Blood. 2012 Jun 14; 119(24):5782-94.
    View in: PubMed
  12. Bianchi G, Kumar S, Ghobrial IM, Roccaro AM. Cell Trafficking in Multiple Myeloma. Open J Hematol. 2012 Feb 21; 3(Suppl 1).
    View in: PubMed
  13. Azab AK, Quang P, Azab F, Pitsillides C, Thompson B, Chonghaile T, Patton JT, Maiso P, Monrose V, Sacco A, Ngo HT, Flores LM, Lin CP, Magnani JL, Kung AL, Letai A, Carrasco R, Roccaro AM, Ghobrial IM. P-selectin glycoprotein ligand regulates the interaction of multiple myeloma cells with the bone marrow microenvironment. Blood. 2012 Feb 9; 119(6):1468-78.
    View in: PubMed
  14. Sacco A, Ghobrial IM, Roccaro AM. Anti-Angiogenic Therapies in the Treatment of Waldenstrom's Macroglobulinemia. Curr Cancer Drug Targets. 2011 Nov 1; 11(9):1025-9.
    View in: PubMed
  15. Maiso P, Liu Y, Morgan B, Azab AK, Ren P, Martin MB, Zhang Y, Liu Y, Sacco A, Ngo H, Azab F, Quang P, Rodig SJ, Lin CP, Roccaro AM, Rommel C, Ghobrial IM. Defining the role of TORC1/2 in multiple myeloma. Blood. 2011 Dec 22; 118(26):6860-70.
    View in: PubMed
  16. Azab F, Azab AK, Maiso P, Calimeri T, Flores L, Liu Y, Quang P, Roccaro AM, Sacco A, Ngo HT, Zhang Y, Morgan BL, Carrasco RD, Ghobrial IM. Eph-B2/ephrin-B2 interaction plays a major role in the adhesion and proliferation of Waldenstrom's macroglobulinemia. Clin Cancer Res. 2012 Jan 1; 18(1):91-104.
    View in: PubMed
  17. Ghobrial IM, Maiso P, Azab A, Liu Y, Zhang Y, Issa G, Azab F, Sacco A, Quang P, Ngo H, Roccaro A. The bone marrow microenvironment in waldenstrom macroglobulinemia. Ther Adv Hematol. 2011 Aug; 2(4):267-72.
    View in: PubMed
  18. Issa GC, Leblebjian H, Roccaro AM, Ghobrial IM. New insights into the pathogenesis and treatment of Waldenstrom macroglobulinemia. Curr Opin Hematol. 2011 Jul; 18(4):260-5.
    View in: PubMed
  19. Ghobrial IM, Zhang Y, Liu Y, Ngo H, Azab F, Sacco A, Azab A, Maiso P, Morgan B, Quang P, Issa GC, Leleu X, Roccaro AM. Targeting the bone marrow in Waldenstrom macroglobulinemia. Clin Lymphoma Myeloma Leuk. 2011 Jun; 11 Suppl 1:S65-9.
    View in: PubMed
  20. Azab AK, Azab F, Quang P, Maiso P, Sacco A, Ngo HT, Liu Y, Zhang Y, Morgan BL, Roccaro AM, Ghobrial IM. FGFR3 is overexpressed waldenstrom macroglobulinemia and its inhibition by Dovitinib induces apoptosis and overcomes stroma-induced proliferation. Clin Cancer Res. 2011 Jul 1; 17(13):4389-99.
    View in: PubMed
  21. C Potts B, X Albitar M, C Anderson K, Baritaki S, Berkers C, Bonavida B, Chandra J, Chauhan D, C Cusack J, Fenical W, M Ghobrial I, Groll M, R Jensen P, S Lam K, K Lloyd G, McBride W, J McConkey D, P Miller C, T C Neuteboom S, Oki Y, Ovaa H, Pajonk F, G Richardson P, M Roccaro A, M Sloss C, A Spear M, Valashi E, Younes A, Palladino MA. Marizomib, a proteasome inhibitor for all seasons: preclinical profile and a framework for clinical trials. Curr Cancer Drug Targets. 2011 Mar; 11(3):254-84.
    View in: PubMed
  22. Sacco A, Aujay M, Morgan B, Azab AK, Maiso P, Liu Y, Zhang Y, Azab F, Ngo HT, Issa GC, Quang P, Roccaro AM, Ghobrial IM. Carfilzomib-dependent selective inhibition of the chymotrypsin-like activity of the proteasome leads to antitumor activity in Waldenstrom's Macroglobulinemia. Clin Cancer Res. 2011 Apr 1; 17(7):1753-64.
    View in: PubMed
  23. Ghobrial IM, Weller E, Vij R, Munshi NC, Banwait R, Bagshaw M, Schlossman R, Leduc R, Chuma S, Kunsman J, Laubach J, Jakubowiak AJ, Maiso P, Roccaro A, Armand P, Dollard A, Warren D, Harris B, Poon T, Sam A, Rodig S, Anderson KC, Richardson PG. Weekly bortezomib in combination with temsirolimus in relapsed or relapsed and refractory multiple myeloma: a multicentre, phase 1/2, open-label, dose-escalation study. Lancet Oncol. 2011 Mar; 12(3):263-72.
    View in: PubMed
  24. Ghobrial IM, Zhang Y, Liu Y, Ngo H, Azab F, Sacco A, Azab A, Maiso P, Morgan B, Quang P, Issa G, Roccaro A. The bone marrow niche in Waldenström's macroglobulinemia. Clin Lymphoma Myeloma Leuk. 2011 Feb; 11(1):118-20.
    View in: PubMed
  25. Sacco A, Maiso P, Azab A, Azab F, Zhang Y, Liu Y, Ngo HT, Morgan B, Quang P, Issa G, Ghobrial IM, Roccaro AM. Key role of microRNAs in Waldenström's macroglobulinemia pathogenesis. Clin Lymphoma Myeloma Leuk. 2011 Feb; 11(1):109-11.
    View in: PubMed
  26. Calvo KR, Landgren O, Roccaro AM, Ghobrial IM. Role of microRNAs from monoclonal gammopathy of undetermined significance to multiple myeloma. Semin Hematol. 2011 Jan; 48(1):39-45.
    View in: PubMed
  27. Issa GC, Ghobrial IM, Roccaro AM. Novel agents in Waldenström macroglobulinemia. Clin Investig (Lond). 2011; 1(6):815-824.
    View in: PubMed
  28. Sacco A, Roccaro A, Ghobrial IM. Role of dual PI3/Akt and mTOR inhibition in Waldenstrom's Macroglobulinemia. Oncotarget. 2010 Nov; 1(7):578-82.
    View in: PubMed
  29. Sacco A, Issa GC, Zhang Y, Liu Y, Maiso P, Ghobrial IM, Roccaro AM. Epigenetic modifications as key regulators of Waldenstrom's Macroglobulinemia biology. J Hematol Oncol. 2010; 3:38.
    View in: PubMed
  30. Sacco A, Ghobrial IM, Roccaro AM. Epigenetics in Waldenström's macroglobulinemia. Epigenomics. 2010 Oct; 2(5):691-6.
    View in: PubMed
  31. Roccaro AM, Sacco A, Jia X, Azab AK, Maiso P, Ngo HT, Azab F, Runnels J, Quang P, Ghobrial IM. microRNA-dependent modulation of histone acetylation in Waldenstrom macroglobulinemia. Blood. 2010 Sep 2; 116(9):1506-14.
    View in: PubMed
  32. Sacco A, Leleu X, Rossi G, Ghobrial IM, Roccaro AM. Novel agents in Waldenstrom Macroglobulinemia. Open J Hematol. 2010 May 28; 1.
    View in: PubMed
  33. Roccaro AM, Sacco A, Aujay M, Ngo HT, Azab AK, Azab F, Quang P, Maiso P, Runnels J, Anderson KC, Demo S, Ghobrial IM. Selective inhibition of chymotrypsin-like activity of the immunoproteasome and constitutive proteasome in Waldenstrom macroglobulinemia. Blood. 2010 May 20; 115(20):4051-60.
    View in: PubMed
  34. Ghobrial IM, Roccaro A, Hong F, Weller E, Rubin N, Leduc R, Rourke M, Chuma S, Sacco A, Jia X, Azab F, Azab AK, Rodig S, Warren D, Harris B, Varticovski L, Sportelli P, Leleu X, Anderson KC, Richardson PG. Clinical and translational studies of a phase II trial of the novel oral Akt inhibitor perifosine in relapsed or relapsed/refractory Waldenstrom's macroglobulinemia. Clin Cancer Res. 2010 Feb 1; 16(3):1033-41.
    View in: PubMed
  35. Stedman J, Roccaro A, Leleu X, Ghobrial IM. New Therapeutic Approaches for Waldenstrom Macroglobulinemia. Drugs Future. 2010 Jan; 35(1):53-58.
    View in: PubMed
  36. Roccaro AM, Sacco A, Husu EN, Pitsillides C, Vesole S, Azab AK, Azab F, Melhem M, Ngo HT, Quang P, Maiso P, Runnels J, Liang MC, Wong KK, Lin C, Ghobrial IM. Dual targeting of the PI3K/Akt/mTOR pathway as an antitumor strategy in Waldenstrom macroglobulinemia. Blood. 2010 Jan 21; 115(3):559-69.
    View in: PubMed
  37. Stedman J, Roccaro A, Ghobrial IM. Individualizing treatment for Waldenstrom's macroglobulinemia. Expert Rev Hematol. 2009 Oct; 2(5):473-6.
    View in: PubMed
  38. Ngo HT, Azab AK, Farag M, Jia X, Melhem MM, Runnels J, Roccaro AM, Azab F, Sacco A, Leleu X, Anderson KC, Ghobrial IM. Src tyrosine kinase regulates adhesion and chemotaxis in Waldenstrom macroglobulinemia. Clin Cancer Res. 2009 Oct 1; 15(19):6035-41.
    View in: PubMed
  39. Venon MD, Roccaro AM, Gay J, Moreau AS, Dulery R, Facon T, Ghobrial IM, Leleu X. Front line treatment of elderly multiple myeloma in the era of novel agents. Biologics. 2009; 3:99-109.
    View in: PubMed
  40. Azab AK, Azab F, Blotta S, Pitsillides CM, Thompson B, Runnels JM, Roccaro AM, Ngo HT, Melhem MR, Sacco A, Jia X, Anderson KC, Lin CP, Rollins BJ, Ghobrial IM. RhoA and Rac1 GTPases play major and differential roles in stromal cell-derived factor-1-induced cell adhesion and chemotaxis in multiple myeloma. Blood. 2009 Jul 16; 114(3):619-29.
    View in: PubMed
  41. Laubach JP, Mitsiades CS, Roccaro AM, Ghobrial IM, Anderson KC, Richardson PG. Clinical challenges associated with bortezomib therapy in multiple myeloma and Waldenströms Macroglobulinemia. Leuk Lymphoma. 2009 May; 50(5):694-702.
    View in: PubMed
  42. Roccaro AM, Sacco A, Thompson B, Leleu X, Azab AK, Azab F, Runnels J, Jia X, Ngo HT, Melhem MR, Lin CP, Ribatti D, Rollins BJ, Witzig TE, Anderson KC, Ghobrial IM. MicroRNAs 15a and 16 regulate tumor proliferation in multiple myeloma. Blood. 2009 Jun 25; 113(26):6669-80.
    View in: PubMed
  43. Skert C, Damiani D, Michelutti A, Patriarca F, Arpinati M, Filì C, Lucchi P, Malagola M, Bergonzi C, Roccaro A, Peli A, Ricotta D, Caimi L, Fanin R, Baccarani M, Russo D. Kinetics of Th1/Th2 cytokines and lymphocyte subsets to predict chronic GVHD after allo-SCT: results of a prospective study. Bone Marrow Transplant. 2009 Dec; 44(11):729-37.
    View in: PubMed
  44. Pascal L, Gay J, Willekens C, Wemeau M, Balkaran S, Robu D, Roccaro A, Morel P, Ghobrial I, Leleu X. Bortezomib and Waldenstrom's macroglobulinemia. Expert Opin Pharmacother. 2009 Apr; 10(5):909-16.
    View in: PubMed
  45. Leleu X, Tamburini J, Roccaro A, Morel P, Soumerai J, Lévy V, Wemeau M, Balkaran S, Poulain S, Hunter ZR, Ghobrial IM, Treon SP, Leblond V. Balancing risk versus benefit in the treatment of Waldenström's Macroglobulinemia patients with nucleoside analogue-based therapy. Clin Lymphoma Myeloma. 2009 Mar; 9(1):71-3.
    View in: PubMed
  46. Roccaro AM, Sacco A, Leleu X, Azab AK, Azab F, Runnels J, Jia X, Ngo HT, Melhem M, Moreau AS, Ghobrial IM. Role of proteasome inhibition in Waldenström's macroglobulinemia. Clin Lymphoma Myeloma. 2009 Mar; 9(1):94-6.
    View in: PubMed
  47. Ghobrial IM, Leleu X, Azab AK, Runnels J, Jia X, Ngo H, Melhem M, Azab F, Sacco A, Quang P, Burwick N, Moreau AS, Husu E, Farag M, Roccaro A. Novel therapeutic agents in Waldenström's macroglobulinemia. Clin Lymphoma Myeloma. 2009 Mar; 9(1):84-6.
    View in: PubMed
  48. Leleu X, Hunter ZR, Xu L, Roccaro AM, Moreau AS, Santos DD, Hatjiharissi E, Bakthavachalam V, Adamia S, Ho AW, Soumerai J, Patterson CJ, Manning RJ, Hamilton S, Verselis S, Fox E, Carrasco R, Ghobrial IM, Treon SP. Expression of regulatory genes for lymphoplasmacytic cell differentiation in Waldenstrom Macroglobulinemia. Br J Haematol. 2009 Apr; 145(1):59-63.
    View in: PubMed
  49. Azab AK, Runnels JM, Pitsillides C, Moreau AS, Azab F, Leleu X, Jia X, Wright R, Ospina B, Carlson AL, Alt C, Burwick N, Roccaro AM, Ngo HT, Farag M, Melhem MR, Sacco A, Munshi NC, Hideshima T, Rollins BJ, Anderson KC, Kung AL, Lin CP, Ghobrial IM. CXCR4 inhibitor AMD3100 disrupts the interaction of multiple myeloma cells with the bone marrow microenvironment and enhances their sensitivity to therapy. Blood. 2009 Apr 30; 113(18):4341-51.
    View in: PubMed
  50. Leleu X, Gay J, Roccaro AM, Moreau AS, Poulain S, Dulery R, Champs BB, Robu D, Ghobrial IM. Update on therapeutic options in Waldenström macroglobulinemia. Eur J Haematol. 2009 Jan; 82(1):1-12.
    View in: PubMed
  51. Roccaro AM, Sacco A, Chen C, Runnels J, Leleu X, Azab F, Azab AK, Jia X, Ngo HT, Melhem MR, Burwick N, Varticovski L, Novina CD, Rollins BJ, Anderson KC, Ghobrial IM. microRNA expression in the biology, prognosis, and therapy of Waldenström macroglobulinemia. Blood. 2009 Apr 30; 113(18):4391-402.
    View in: PubMed
  52. Leleu X, Soumerai J, Roccaro A, Hatjiharissi E, Hunter ZR, Manning R, Ciccarelli BT, Sacco A, Ioakimidis L, Adamia S, Moreau AS, Patterson CJ, Ghobrial IM, Treon SP. Increased incidence of transformation and myelodysplasia/acute leukemia in patients with Waldenström macroglobulinemia treated with nucleoside analogs. J Clin Oncol. 2009 Jan 10; 27(2):250-5.
    View in: PubMed
  53. Leleu X, Xu L, Jia X, Sacco A, Farag M, Hunter ZR, Moreau AS, Ngo HT, Hatjiharissi E, Ho AW, Santos DD, Adamia S, O'Connor K, Ciccarelli B, Soumerai J, Manning RJ, Patterson CJ, Roccaro AM, Ghobrial IM, Treon SP. Endoplasmic reticulum stress is a target for therapy in Waldenstrom macroglobulinemia. Blood. 2009 Jan 15; 113(3):626-34.
    View in: PubMed
  54. Roccaro AM, Ghobrial IM, Blotta S, Treon SP, Malagola M, Anderson KC, Richardson PG, Russo D. Advances in the treatment of monoclonal gammopaties: The emerging role of targeted therapy in plasma cell dyscrasias. Biologics. 2008 Sep; 2(3):419-31.
    View in: PubMed
  55. Malagola M, Peli A, Damiani D, Candoni A, Tiribelli M, Martinelli G, Piccaluga PP, Paolini S, De Rosa F, Lauria F, Bocchia M, Gobbi M, Pierri I, Zaccaria A, Zuffa E, Mazza P, Priccolo G, Gugliotta L, Bonini A, Visani G, Skert C, Bergonzi C, Roccaro AM, Filì C, Fanin R, Baccarani M, Russo D. Incidence of bacterial and fungal infections in newly diagnosed acute myeloid leukaemia patients younger than 65 yr treated with induction regimens including fludarabine: retrospective analysis of 224 cases. Eur J Haematol. 2008 Nov; 81(5):354-63.
    View in: PubMed
  56. Leleu X, Roccaro AM, Moreau AS, Dupire S, Robu D, Gay J, Hatjiharissi E, Burwik N, Ghobrial IM. Waldenstrom macroglobulinemia. Cancer Lett. 2008 Oct 18; 270(1):95-107.
    View in: PubMed
  57. Moreau AS, Jia X, Patterson CJ, Roccaro AM, Xu L, Sacco A, O'Connor K, Soumerai J, Ngo HT, Hatjiharissi E, Hunter ZR, Ciccarelli B, Manning R, Ghobrial IM, Leleu X, Treon SP. The HMG-CoA inhibitor, simvastatin, triggers in vitro anti-tumour effect and decreases IgM secretion in Waldenstrom macroglobulinaemia. Br J Haematol. 2008 Sep; 142(5):775-85.
    View in: PubMed
  58. Burwick N, Roccaro AM, Leleu X, Ghobrial IM. Targeted therapies in Waldenström macroglobulinemia. Curr Opin Investig Drugs. 2008 Jun; 9(6):631-7.
    View in: PubMed
  59. Leleu X, Moreau AS, Weller E, Roccaro AM, Coiteux V, Manning R, Nelson M, Leduc R, Robu D, Dupire S, Hatjiharissi E, Burwick N, Darre S, Hennache B, Treon SP, Facon T, Gertz MA, Ghobrial IM. Serum immunoglobulin free light chain correlates with tumor burden markers in Waldenstrom macroglobulinemia. Leuk Lymphoma. 2008 Jun; 49(6):1104-7.
    View in: PubMed
  60. Ngo HT, Leleu X, Lee J, Jia X, Melhem M, Runnels J, Moreau AS, Burwick N, Azab AK, Roccaro A, Azab F, Sacco A, Farag M, Sackstein R, Ghobrial IM. SDF-1/CXCR4 and VLA-4 interaction regulates homing in Waldenstrom macroglobulinemia. Blood. 2008 Jul 1; 112(1):150-8.
    View in: PubMed
  61. Roccaro AM, Leleu X, Sacco A, Moreau AS, Hatjiharissi E, Jia X, Xu L, Ciccarelli B, Patterson CJ, Ngo HT, Russo D, Vacca A, Dammacco F, Anderson KC, Ghobrial IM, Treon SP. Resveratrol exerts antiproliferative activity and induces apoptosis in Waldenström's macroglobulinemia. Clin Cancer Res. 2008 Mar 15; 14(6):1849-58.
    View in: PubMed
  62. Leleu X, Eeckhoute J, Jia X, Roccaro AM, Moreau AS, Farag M, Sacco A, Ngo HT, Runnels J, Melhem MR, Burwick N, Azab A, Azab F, Hunter Z, Hatjiharissi E, Carrasco DR, Treon SP, Witzig TE, Hideshima T, Brown M, Anderson KC, Ghobrial IM. Targeting NF-kappaB in Waldenstrom macroglobulinemia. Blood. 2008 May 15; 111(10):5068-77.
    View in: PubMed
  63. Moreau AS, Sebti Y, Duhamel A, Roccaro AM, Coiteux V, Gastinne T, Le Friec G, Burwick N, Amiot L, Ho AW, Poulain S, Hennache B, Hunter ZR, Dessaint JP, Ghobrial IM, Treon SP, Facon T, Zorn E, Leleu X. Clinical relevance of soluble HLA class I molecules in Waldenstrom Macroglobulinemia. Eur J Haematol. 2008 Jun; 80(6):503-9.
    View in: PubMed
  64. Roccaro AM, Leleu X, Sacco A, Jia X, Melhem M, Moreau AS, Ngo HT, Runnels J, Azab A, Azab F, Burwick N, Farag M, Treon SP, Palladino MA, Hideshima T, Chauhan D, Anderson KC, Ghobrial IM. Dual targeting of the proteasome regulates survival and homing in Waldenstrom macroglobulinemia. Blood. 2008 May 1; 111(9):4752-63.
    View in: PubMed
  65. Huston A, Leleu X, Jia X, Moreau AS, Ngo HT, Runnels J, Anderson J, Alsayed Y, Roccaro A, Vallet S, Hatjiharissi E, Tai YT, Sportelli P, Munshi N, Richardson P, Hideshima T, Roodman DG, Anderson KC, Ghobrial IM. Targeting Akt and heat shock protein 90 produces synergistic multiple myeloma cell cytotoxicity in the bone marrow microenvironment. Clin Cancer Res. 2008 Feb 1; 14(3):865-74.
    View in: PubMed
  66. Leleu X, Jia X, Runnels J, Ngo HT, Moreau AS, Farag M, Spencer JA, Pitsillides CM, Hatjiharissi E, Roccaro A, O'Sullivan G, McMillin DW, Moreno D, Kiziltepe T, Carrasco R, Treon SP, Hideshima T, Anderson KC, Lin CP, Ghobrial IM. The Akt pathway regulates survival and homing in Waldenstrom macroglobulinemia. Blood. 2007 Dec 15; 110(13):4417-26.
    View in: PubMed
  67. Treon SP, Hatjiharissi E, Leleu X, Moreau AS, Roccaro A, Hunter ZR, Soumerai JD, Ciccarelli B, Xu L, Sacco A, Ngo HT, Jia X, Yang C, Adamia S, Branagan AR, Ho AW, Santos DD, Tournilhac O, Manning RJ, Leduc R, O'Connor K, Nelson M, Patterson CJ, Ghobrial I. Novel agents in the treatment of Waldenström's macroglobulinemia. Clin Lymphoma Myeloma. 2007 Aug; 7 Suppl 5:S199-206.
    View in: PubMed
  68. Ghobrial J, Ghobrial IM, Mitsiades C, Leleu X, Hatjiharissi E, Moreau AS, Roccaro A, Schlossman R, Hideshima T, Anderson KC, Richardson P. Novel therapeutic avenues in myeloma: changing the treatment paradigm. Oncology (Williston Park). 2007 Jun; 21(7):785-92; discussion 798-800.
    View in: PubMed
  69. Malagola M, Damiani D, Martinelli G, Michelutti A, Cesana B, Vivo AD, Piccaluga PP, Ottaviani E, Candoni A, Geromin A, Tiribelli M, Fanin R, Testoni N, Lauria F, Bocchia M, Gobbi M, Pierri I, Zaccaria A, Zuffa E, Mazza P, Priccolo G, Gugliotta L, Bonini A, Visani G, Skert C, Bergonzi C, Roccaro AM, Filí C, Baccarani M, Russo D. Case-control study of multidrug resistance phenotype and response to induction treatment including or not fludarabine in newly diagnosed acute myeloid leukaemia patients. Br J Haematol. 2007 Jan; 136(1):87-95.
    View in: PubMed
  70. Roccaro AM, Hideshima T, Richardson PG, Russo D, Ribatti D, Vacca A, Dammacco F, Anderson KC. Bortezomib as an antitumor agent. Curr Pharm Biotechnol. 2006 Dec; 7(6):441-8.
    View in: PubMed
  71. Roccaro AM, Vacca A, Ribatti D. Bortezomib in the treatment of cancer. Recent Pat Anticancer Drug Discov. 2006 Nov; 1(3):397-403.
    View in: PubMed
  72. Ribatti D, Nico B, Crivellato E, Roccaro AM, Vacca A. The history of the angiogenic switch concept. Leukemia. 2007 Jan; 21(1):44-52.
    View in: PubMed
  73. Ranieri G, Roccaro AM, Vacca A, Ribatti D. Thymidine phosphorylase (platelet-derived endothelial cell growth factor) as a target for capecitabine: from biology to the bedside. Recent Pat Anticancer Drug Discov. 2006 Jun; 1(2):171-83.
    View in: PubMed
  74. Nico B, Corsi P, Ria R, Crivellato E, Vacca A, Roccaro AM, Mangieri D, Ribatti D, Roncali L. Increased matrix-metalloproteinase-2 and matrix-metalloproteinase-9 expression in the brain of dystrophic mdx mouse. Neuroscience. 2006 Jul 7; 140(3):835-48.
    View in: PubMed
  75. Roccaro AM, Hideshima T, Raje N, Kumar S, Ishitsuka K, Yasui H, Shiraishi N, Ribatti D, Nico B, Vacca A, Dammacco F, Richardson PG, Anderson KC. Bortezomib mediates antiangiogenesis in multiple myeloma via direct and indirect effects on endothelial cells. Cancer Res. 2006 Jan 1; 66(1):184-91.
    View in: PubMed
  76. Ishitsuka K, Hideshima T, Hamasaki M, Raje N, Kumar S, Podar K, Le Gouill S, Shiraishi N, Yasui H, Roccaro AM, Tai YZ, Chauhan D, Fram R, Tamura K, Jain J, Anderson KC. Novel inosine monophosphate dehydrogenase inhibitor VX-944 induces apoptosis in multiple myeloma cells primarily via caspase-independent AIF/Endo G pathway. Oncogene. 2005 Sep 1; 24(38):5888-96.
    View in: PubMed
  77. Yasui H, Hideshima T, Raje N, Roccaro AM, Shiraishi N, Kumar S, Hamasaki M, Ishitsuka K, Tai YT, Podar K, Catley L, Mitsiades CS, Richardson PG, Albert R, Brinkmann V, Chauhan D, Anderson KC. FTY720 induces apoptosis in multiple myeloma cells and overcomes drug resistance. Cancer Res. 2005 Aug 15; 65(16):7478-84.
    View in: PubMed
  78. Kumar S, Raje N, Hideshima T, Ishitsuka K, Roccaro A, Shiraishi N, Hamasaki M, Yasui H, Munshi NC, Richardson P, Figg WD, Anderson KC. Antimyeloma activity of two novel N-substituted and tetraflourinated thalidomide analogs. Leukemia. 2005 Jul; 19(7):1253-61.
    View in: PubMed
  79. Ishitsuka K, Hideshima T, Hamasaki M, Raje N, Kumar S, Hideshima H, Shiraishi N, Yasui H, Roccaro AM, Richardson P, Podar K, Le Gouill S, Chauhan D, Tamura K, Arbiser J, Anderson KC. Honokiol overcomes conventional drug resistance in human multiple myeloma by induction of caspase-dependent and -independent apoptosis. Blood. 2005 Sep 1; 106(5):1794-800.
    View in: PubMed
  80. Raje N, Kumar S, Hideshima T, Roccaro A, Ishitsuka K, Yasui H, Shiraishi N, Chauhan D, Munshi NC, Green SR, Anderson KC. Seliciclib (CYC202 or R-roscovitine), a small-molecule cyclin-dependent kinase inhibitor, mediates activity via down-regulation of Mcl-1 in multiple myeloma. Blood. 2005 Aug 1; 106(3):1042-7.
    View in: PubMed
  81. Yasui H, Hideshima T, Hamasaki M, Roccaro AM, Shiraishi N, Kumar S, Tassone P, Ishitsuka K, Raje N, Tai YT, Podar K, Chauhan D, Leoni LM, Kanekal S, Elliott G, Munshi NC, Anderson KC. SDX-101, the R-enantiomer of etodolac, induces cytotoxicity, overcomes drug resistance, and enhances the activity of dexamethasone in multiple myeloma. Blood. 2005 Jul 15; 106(2):706-12.
    View in: PubMed
  82. Ranieri G, Ria R, Roccaro AM, Vacca A, Ribatti D. Development of vasculature targeting strategies for the treatment of chronic inflammatory diseases. Curr Drug Targets Inflamm Allergy. 2005 Feb; 4(1):13-22.
    View in: PubMed
  83. Roccaro AM, Russo F, Cirulli T, Di Pietro G, Vacca A, Dammacco F. Antiangiogenesis for rheumatoid arthritis. Curr Drug Targets Inflamm Allergy. 2005 Feb; 4(1):27-30.
    View in: PubMed
  84. Ribatti D, Crivellato E, Roccaro AM, Ria R, Vacca A. Mast cell contribution to angiogenesis related to tumour progression. Clin Exp Allergy. 2004 Nov; 34(11):1660-4.
    View in: PubMed
  85. Ribatti D, Scavelli C, Roccaro AM, Crivellato E, Nico B, Vacca A. Hematopoietic cancer and angiogenesis. Stem Cells Dev. 2004 Oct; 13(5):484-95.
    View in: PubMed
  86. Ria R, Roccaro AM, Merchionne F, Vacca A, Dammacco F, Ribatti D. Vascular endothelial growth factor and its receptors in multiple myeloma. Leukemia. 2003 Oct; 17(10):1961-6.
    View in: PubMed
  87. Ribatti D, Vacca A, Roccaro AM, Crivellato E, Presta M. Erythropoietin as an angiogenic factor. Eur J Clin Invest. 2003 Oct; 33(10):891-6.
    View in: PubMed
  88. Ribatti D, Molica S, Vacca A, Nico B, Crivellato E, Roccaro AM, Dammacco F. Tryptase-positive mast cells correlate positively with bone marrow angiogenesis in B-cell chronic lymphocytic leukemia. Leukemia. 2003 Jul; 17(7):1428-30.
    View in: PubMed
  89. Fanelli M, Sarmiento R, Gattuso D, Carillio G, Capaccetti B, Vacca A, Roccaro AM, Gasparini G. Thalidomide: a new anticancer drug? Expert Opin Investig Drugs. 2003 Jul; 12(7):1211-25.
    View in: PubMed
  90. Molica S, Vacca A, Ribatti D, Cuneo A, Cavazzini F, Levato D, Vitelli G, Tucci L, Roccaro AM, Dammacco F. Prognostic value of enhanced bone marrow angiogenesis in early B-cell chronic lymphocytic leukemia. Blood. 2002 Nov 1; 100(9):3344-51.
    View in: PubMed
  91. Ria R, Loverro G, Vacca A, Ribatti D, Cormio G, Roccaro AM, Selvaggi L. Angiogenesis extent and expression of matrix metalloproteinase-2 and -9 agree with progression of ovarian endometriomas. Eur J Clin Invest. 2002 Mar; 32(3):199-206.
    View in: PubMed
  92. Vacca A, Ribatti D, Roccaro AM, Frigeri A, Dammacco F. Bone marrow angiogenesis in patients with active multiple myeloma. Semin Oncol. 2001 Dec; 28(6):543-50.
    View in: PubMed
  93. Ribatti D, Vacca A, De Falco G, Roccaro A, Roncali L, Dammacco F. Angiogenesis, angiogenic factor expression and hematological malignancies. Anticancer Res. 2001 Nov-Dec; 21(6B):4333-9.
    View in: PubMed
  94. Ribatti D, De Falco G, Vacca A, Nico B, Errede M, Roccaro AM, Roncali L, Dammacco F. Coordinate immunoreactivity to vascular endothelial growth factor receptor-2 and its ligand suggests a paracrine regulation during the development of the vascular system in the chick embryo bursa of Fabricius. Int J Mol Med. 2001 Apr; 7(4):365-8.
    View in: PubMed
  95. Vacca A, Ribatti D, Roccaro AM, Ria R, Palermo L, Dammacco F. Bone marrow angiogenesis and plasma cell angiogenic and invasive potential in patients with active multiple myeloma. Acta Haematol. 2001; 106(4):162-9.
    View in: PubMed
Local representatives can answer questions about the Profiles website or help with editing a profile or issues with profile data. For assistance with this profile: HMS/HSDM faculty should contact Human Resources at faculty_serviceshms.harvard.edu.
Roccaro's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts
_
Co-Authors
_
Similar People
_
Same Department